Amazon may be in the final phase of its decision to enter the online prescription drug sales market, according to analysts. Although Amazon has declined to comment, experts believe the company will decide before Thanksgiving whether it will enter the marketplace.
Amazon may be in the final phase of its decision to enter the online prescription drug sales market, according to analysts. Although Amazon has declined to comment, experts believe the company will decide before Thanksgiving whether it will enter the marketplace.
Earlier this year, Amazon had reportedly hired a manager to lead the company’s research into the pharmacy market and related business strategies, and was said to be recruiting among pharmacy experts. The head of Amazon’s consumables division, which includes groceries, has kicked off research into online prescription drugs sales, and the company also hired Mark Lyons, formerly of Premera Blue Cross, to build an internal pharmacy benefits manager (PBM) program for Amazon employees, which could potentially be increased in scope.
Still, analysts note that Amazon’s possible move to online pharmacy sales is not a sure thing, as the company is well aware that the drug supply chain is complex and full of regulatory hurdles and well-established competition.
Goldman Sachs issued a report in August 2017 forecasting that Amazon would look to improve price transparency for pharmaceutical consumers and reduce out-of-pocket costs, but said that the retailer would likely start by speeding up the drug-delivery process and facilitating at-home delivery. The Goldman Sachs report speculates that Amazon might start by partnering with a PBM to provide access to patient data and allow the company to cross-sell related products.
Stephen Buck, co-founder of GoodRx—a website and mobile app that tracks prescription drug prices in more than 70,000 US pharmacies and offers coupons to consumers—told CNBC that Amazon could introduce a great deal of transparency into what drugs really cost. Buck predicts an Amazon PBM could compete with big PBMs like Express Scripts and CVS Health. Buck believes that online pharmacy sales is a $25 billion to $50 billion market opportunity for Amazon, but notes that the company would have to contend with challenges presented by prescription transfer laws (regulations guiding transferring prescriptions between pharmacies and for controlled substances) and electronic prescribing.
Amazon CEO Jeff Bezos was previously involved in sales of online consumer health products through Drugstore.com in the late 1990s, when Amazon bought 40% of the business. However, Drugstore.com was sold to Walgreens, which eventually closed the site in 2016. Amazon already sells medical supplies and equipment in the United States, and has launched same-day delivery for pharmaceuticals in Japan, where local pharmacists must approve medication delivery to patients.
Writing in Pharmacy Times in May 2017, Timothy Aungst, PharmD, asked whether Amazon’s entry into online prescription drug sales will mean drone-delivered medications, same-day delivery, and pop-up recommendations for products related to an individual’s health based on his or her past purchases. “Points on your Amazon Prime Account?” he asks. “And of course, recommended products for your health and needs because they will figure out your past medical history from all this and make money off of your health.”
Aungst suggests that if Amazon enters the online pharmaceuticals market, its entry could create competition for other large-scale players in pharmacy, a scenario that may benefit patients by reducing costs.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Eye on Pharma: Adalimumab Updates; New Eylea Biosimilar Lawsuit; Canada Gains Stelara Biosimilar
November 22nd 2023Several companies make moves to further their adalimumab biosimilars, Regeneron sues Celltrion over biosimilar for Eylea (aflibercept), and Health Canada grants marketing authorization for biosimilar referencing Stelara (ustekinumab).
Biosimilars Business Roundup For August 2023—Podcast Edition
September 5th 2023On this episode, we’re giving an overview of some of the biggest stories in the business space regarding biosimilars, like the approval of the first neurology biosimilar, growth projections from company quarterly expense reports, and some analyses about the health of the market.
AMCP Nexus: Panelists Share Current Scope of Biosimilar Industry
October 26th 2023Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.
Report: Conflicting Guidelines, Rebate Walls Are Major Factors Determining Biosimilar Uptake
October 24th 2023Samsung Bioepis’ most recent biosimilar market report identified inconsistent medical guidelines, challenges with access and rebates, and acute vs chronic treatment duration as major factors influencing biosimilar uptake in the United States.